NFKB2: A Potential Drug Target and Biomarker for Inflammatory Diseases

Target Name: NFKB2

NCBI ID: G4791

NFKB2

NFKB2: A Potential Drug Target and Biomarker for Inflammatory Diseases

Nuclear factor kappa B2 (NFKB2) is a key transcription factor that plays a crucial role in the regulation of gene expression and inflammation. NFKB2 is highly expressed in various tissues and cells, including immune and inflammatory cells, and has been implicated in the development and progression of numerous inflammatory diseases, including autoimmune disorders, atherosclerosis, and neuroinflammatory diseases. As such, targeting NFKB2 has the potential to offer new therapeutic approaches for the treatment of these debilitating conditions. In this article, we will explore the NFKB2 protein, its functions, and its potential as a drug target and biomarker.

The NFKB2 Protein

NFKB2 is a 220-kDa protein that is expressed in various tissues, including liver, spleen, lung, heart, kidney, and brain. NFKB2 is composed of a 166 amino acid protein and a 64 amino acid N-terminal transmembrane region. The NFKB2 protein consists of two distinct domains: the N-terminal domain (NTD), which contains a 126 amino acid伪-helices, and the C-terminal domain (CTD), which contains a 94 amino acid 尾-sheet and a 22 amino acid 纬-helices.

The NFKB2 gene

The NFKB2 gene is located on chromosome 6p21.2 and has a transcribed start site at position -111.1 base pairs upstream of the gene. The NFKB2 gene encodes a protein that contains 1,944 amino acids, with the majority of the protein consisting of 115-amino acid residues. The NFKB2 protein is predominantly expressed in the cytoplasm of various cell types and has been shown to be involved in the regulation of gene expression and cellular processes, including cell adhesion, migration, and survival.

NFKB2 Functions

NFKB2 is involved in the regulation of gene expression and has been implicated in the development and progression of numerous inflammatory diseases. NFKB2 has been shown to play a key role in the regulation of inflammation, immune cell function, and cell survival.

NFKB2 is involved in the regulation of inflammation

NFKB2 has been shown to be involved in the regulation of inflammatory responses. NFKB2 has been shown to activate immune cells and induce their production of pro-inflammatory cytokines, such as TNF-伪, IL-1, and IL-6. These cytokines contribute to the recruitment of immune cells to sites of infection, tissue damage, and inflammation.

NFKB2 is involved in the regulation of immune cell function

NFKB2 has also been shown to be involved in the regulation of immune cell function. NFKB2 has been shown to play a key role in the regulation of T cell development and function, as well as their proliferation and survival. NFKB2 has been shown to recruit T cells to sites of infection and promote their proliferation, while also regulating their apoptosis.

NFKB2 is involved in cell survival

NFKB2 has also been shown to be involved in cell survival. NFKB2 has been shown to play a key role in the regulation of cell survival and apoptosis, as well as cell cycle progression. NFKB2 has been shown to regulate the G1/S transition and cell cycle progression, as well as

Protein Name: Nuclear Factor Kappa B Subunit 2

Functions: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer

The "NFKB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NFKB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets